Dutch-US biotech raises $61M to test ex-Mitsubishi Tanabe drug for schizophrenia

Kyle LaHucik

Senior Reporter

Multiple biotech companies have made noise in schizophrenia R&D this year, with a landmark drug approval request and several large financings, and on Tuesday morning …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dutch-US biotech raises $61M to test ex-Mitsubishi Tanabe drug for schizophrenia

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Dutch-US biotech rais­es $61M to test ex-Mit­subishi Tan­abe drug for schiz­o­phre­nia

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Dutch-US biotech raises $61M to test ex-Mitsubishi Tanabe drug for schizophrenia